LOXL2 and atherosclerosis: Therapeutic interventions targeting LOX, such as β-aminopropionitrile (BAPN) and LOXL2-specific inhibitors like GSK2878163, have demonstrated efficacy in mitigating ECM cross-linking and decelerating atherosclerosis progression in animal models (20).